| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| T1015 |
Clinic visit/encounter, all-inclusive |
57,486 |
56,852 |
$12.73M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
25,677 |
24,070 |
$90K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
13,143 |
12,302 |
$62K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,619 |
2,270 |
$49K |
| 99215 |
Prolong outpt/office vis |
2,708 |
2,549 |
$14K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
5,112 |
4,833 |
$12K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
2,808 |
2,642 |
$12K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
6,389 |
6,005 |
$7K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
2,789 |
2,639 |
$5K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
4,642 |
4,386 |
$3K |
| G0467 |
Federally qualified health center (fqhc) visit, established patient; a medically-necessary, face-to-face encounter (one-on-one) between an established patient and a fqhc practitioner during which time one or more fqhc services are rendered and includes a typical bundle of medicare-covered services that would be furnished per diem to a patient receiving a fqhc visit |
93 |
80 |
$3K |
| 93000 |
|
1,034 |
972 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,040 |
1,935 |
$2K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
123 |
117 |
$2K |
| 99000 |
|
5,511 |
5,201 |
$1K |
| 81025 |
|
2,736 |
2,536 |
$892.46 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
57 |
46 |
$891.33 |
| 81002 |
|
6,270 |
5,930 |
$785.70 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
799 |
753 |
$323.80 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,435 |
1,382 |
$302.48 |
| 80047 |
|
468 |
434 |
$285.39 |
| 85007 |
|
1,238 |
1,165 |
$232.61 |
| 89240 |
|
793 |
751 |
$133.67 |
| 87420 |
|
190 |
182 |
$96.44 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
68 |
63 |
$38.70 |
| 36415 |
Collection of venous blood by venipuncture |
2,199 |
2,137 |
$28.20 |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
9,659 |
9,280 |
$6.33 |
| 82962 |
|
13 |
12 |
$2.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
66 |
65 |
$0.14 |
| 1159F |
|
8,017 |
7,895 |
$0.02 |
| 3079F |
|
3,771 |
3,722 |
$0.00 |
| 3351F |
|
144 |
135 |
$0.00 |
| 3074F |
|
9,769 |
9,582 |
$0.00 |
| 3008F |
|
5,013 |
4,950 |
$0.00 |
| 3075F |
|
1,144 |
1,133 |
$0.00 |
| 1125F |
|
5,449 |
5,361 |
$0.00 |
| 2010F |
|
12,493 |
12,237 |
$0.00 |
| 1126F |
|
1,426 |
1,406 |
$0.00 |
| G9664 |
Patients who are currently statin therapy users or received an order (prescription) for statin therapy |
654 |
643 |
$0.00 |
| 3080F |
|
752 |
739 |
$0.00 |
| 3120F |
|
84 |
82 |
$0.00 |
| 4010F |
|
27 |
27 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
47 |
47 |
$0.00 |
| 84512 |
|
14 |
13 |
$0.00 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
12 |
12 |
$0.00 |
| 87807 |
|
17 |
15 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
13 |
12 |
$0.00 |
| 3077F |
|
1,863 |
1,827 |
$0.00 |
| 3078F |
|
8,364 |
8,192 |
$0.00 |
| 3028F |
|
4,589 |
4,495 |
$0.00 |
| G9920 |
Screening performed and negative |
26 |
26 |
$0.00 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
38 |
38 |
$0.00 |